Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Endocr Pract ; 2024 Jun 12.
Article in English | MEDLINE | ID: mdl-38876181

ABSTRACT

OBJECTIVE: To compare the immunogenicity, safety, and efficacy of Gan & Lee insulin glargine (GL Glargine) with that of the originator insulin glargine (Lantus) in patients with type 1 diabetes mellitus (T1DM). METHODS: This was a phase 3, multicenter, randomized, open-label, equivalence study. Five hundred seventy-six subjects with T1DM were randomized 1:1 to receive either GL Glargine or Lantus treatment for 26 weeks. The primary end point was the percentage of subjects in each treatment group who developed treatment-induced anti-insulin antibody after baseline and up to visit week 26, which was evaluated using a country-adjusted logistic regression model. The study also compared the changes in glycated hemoglobin, and adverse events including hypoglycemia. RESULTS: The percentage of subjects positive for treatment-induced anti-insulin antibody by Week 26 was 25.8% in the GL Glargine treatment group and 25.3% in the Lantus treatment group, with a 90% confidence interval (-5.4, 6.5) of the difference in proportions that fell completely between the similarity margins (-11.3, 11.3). The least squares mean difference between treatment groups for changes in glycated hemoglobin was -0.08 (90% confidence interval: -0.23, 0.06), and the other immunogenicity and safety profiles were comparable. CONCLUSION: GL Glargine demonstrated similar immunogenicity, efficacy, and safety compared to Lantus over 26 weeks in patients with T1DM.

2.
Ann Nutr Metab ; 62(1): 80-5, 2013.
Article in English | MEDLINE | ID: mdl-23296094

ABSTRACT

BACKGROUND/AIMS: In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines. METHODS: The fasting serum acylcarnitine concentrations were determined in 49 T1D, 38 T2D and 38 MetS patients and 40 controls by isotope dilution electrospray ionization tandem mass spectrometry. RESULTS: The acylcarnitine profiles of the 3patient groups shared elements with the controls. Considerably higher levels of almost all short-chain acylcarnitines (p < 0.05) and lower levels of some long-chain acylcarnitines were detected in T2D and MetS patients. The amounts of C3 and C4 carnitine were higher and most of the medium-chain and long-chain acylcarnitine levels were lower (p < 0.05) in T1D and MetS patients than in the controls. In T1D and T2D, the levels of C3 and C4 acylcarnitines were markedly elevated and some long-chain acylcarnitines were lower than the controls (p < 0.05). Moreover, significantly lower concentrations of free- and total carnitine were observed in T1D patients (p < 0.05). CONCLUSIONS: Profound alterations were detected in acylcarnitine profiles in the 3 patient groups. Similarities in the patterns suggest different degrees of involvement of the same metabolic systems in a systems biology approach.


Subject(s)
Carnitine/analogs & derivatives , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 2/blood , Metabolic Syndrome/blood , Adult , Aged , Body Mass Index , Carnitine/blood , Case-Control Studies , Fasting , Female , Humans , Male , Middle Aged , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Young Adult
3.
Orv Hetil ; 149(27): 1263-9, 2008 Jul 06.
Article in Hungarian | MEDLINE | ID: mdl-18579465

ABSTRACT

UNLABELLED: The attainment and maintenance of therapeutic goal of cardiovascular risk factors are of great clinical importance. The effectiveness of cardiovascular risk management is not well characterized during regular care of patients with type 1 diabetes mellitus. AIM: The aim of the study was to estimate the effectiveness of cardiovascular risk management in type 1 diabetic patients. METHODS: Adult patients with type 1 diabetes mellitus (n = 533; 256 men, 277 women; age: 35.6 +/- 11.6 years; duration of diabetes: 18.0 +/- 11.1 years; x +/- SD) were consecutively enrolled from 11 diabetes outpatient departments. Data on medical history, actual treatment, anthropometric and laboratory parameters as well as actual blood pressure were registered, while eating and smoking habits, education level and physical activity were evaluated by standardized questionnaires. The treating goal was set according to the national guideline which corresponds to the current international task force. RESULTS: Of 533 patients, the body mass index target level (< 25 kg/m 2 ) was achieved by 295 (55.5%) patients. Ideal waist circumference (< 80 cm for women and < 94 cm for men) was measured in 140 (50.5%) and in 165 (63.7%) patients, respectively. Optimal glycaemic control (HbA 1c level < 6.5%) was documented in 45 (8.4%) patients. Lipid lowering drugs (statins, fibrates or ezetimibe) were used by 130 patients, among which 53.1% reached the target triglyceride level, 71.5% the target HDL-cholesterol and 27.8% the target LDL-cholesterol levels. Taking the lipid target values together, only 23 (17.7%) patients were at goal. Antihypertensive drugs were used by 173 patients among which 29.5% reached the systolic and 34.8% the diastolic target values (< 130/80 mmHg). Regarding smoking habits, 94 (17.7%) patients were current smokers and 102 (19.2%) ex-smokers. CONCLUSIONS: The attainment of therapeutic goal of cardiovascular risk factors proved to be difficult in a substantial part of patients. Further efforts are needed for attaining and maintaining the established goal of cardiovascular risk management during regular care of adult patients with type 1 diabetes mellitus.


Subject(s)
Anticholesteremic Agents/administration & dosage , Antihypertensive Agents/administration & dosage , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/metabolism , Hypoglycemic Agents/administration & dosage , Metabolic Syndrome/metabolism , Metabolic Syndrome/prevention & control , Adult , Azetidines/administration & dosage , Blood Pressure , Body Mass Index , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Clofibric Acid/administration & dosage , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/physiopathology , Ezetimibe , Female , Glycated Hemoglobin/metabolism , Humans , Hungary , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Male , Metabolic Syndrome/blood , Metabolic Syndrome/etiology , Metabolic Syndrome/physiopathology , Middle Aged , Practice Guidelines as Topic , Risk Assessment , Risk Factors , Surveys and Questionnaires , Treatment Outcome , Triglycerides/blood
4.
Circ J ; 72(1): 40-3, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18159097

ABSTRACT

BACKGROUND: Metabolic syndrome consists of multiple risk factors that are increasing the cardiovascular mortality. The T-1131C variant of the apolipoprotein A5 gene, associated with increased triglycerides, has been found to confer risk for cardiovascular diseases and metabolic syndrome. Because other naturally occurring variants of the gene also correlate with elevated triglycerides, the possible role of 2 common variants, the IVS3+G476A and T1259C, with metabolic syndrome was investigated. METHODS AND RESULTS: A total of 213 metabolic syndrome patients and 142 healthy controls were genotyped by polymerase chain reaction-restriction fragment length polymorphism. Serum triglycerides were increased in carriers compared with non-carriers in both groups (p<0.001); serum cholesterol levels were similar in all genotypes. The IVS3+476A allele frequency was increased in metabolic syndrome patients compared with controls (8.05 vs 2.47%; p<0.05), whereas the 1259C allele frequency did not differ between the groups. Multiple logistic regression analyses adjusted for age, gender, serum total cholesterol, acute myocardial infarction and stroke revealed that the IVS3+476A variant confers risk for development of metabolic syndrome (odds ratio =3.529, 95% confidence interval 1.308-9.029, p=0.009), but the 1259C allele had no such an effect. CONCLUSIONS: Carrying the IVS3+473A allele is associated with elevated triglycerides and confers risk for development of metabolic syndrome, a combination that represents increased risk for development of atherogenic vascular diseases.


Subject(s)
Apolipoproteins A/genetics , Metabolic Syndrome/genetics , Polymorphism, Genetic , Triglycerides/blood , Alleles , Apolipoprotein A-V , Atherosclerosis , Case-Control Studies , Female , Gene Frequency , Genotype , Humans , Hungary/epidemiology , Male , Metabolic Syndrome/etiology , Middle Aged , Regression Analysis , Risk
5.
Orv Hetil ; 148(41): 1923-8, 2007 Oct 14.
Article in Hungarian | MEDLINE | ID: mdl-17921119

ABSTRACT

INTRODUCTION: Continuous glucose monitoring system is a wide spreading method in the control of the therapy of diabetes, nowadays recording the fluctuation of the glucose level between two measurements during the classical glucose measurements. PATIENTS AND METHOD: 79 measurements of 53 diabetic patients were analysed. 48/53 (90.5%) (30 women, 18 men, mean age: 26.3 +/- 16.8 years) were patients with type 1 diabetes, 5/53 (9.5%) (4 women, 1 man, mean age: 58.4 +/- 6.2 years) were patients with type 2 diabetes. After delineating the technical details of this technique, results of the measurements recorded in the authors' patients population are presented reviewing the advantages and disadvantages of the method. During the average measurements of 3-4 days MiniMed apparatus were used. RESULTS: The method proved to be useful in detecting the down-phenomenon and the asymptomatic hypoglycemic events mainly, however, long hyperglycemic periods were seen several times. The method led to change of therapy in 64.5% of all measurements, but the authors present unsuccessful measurements due to the error of the sensor and cases when the results did not help the therapeutic decision. CONCLUSIONS: Authors describe a wide range of indications of the usage of this method based on their own and other authors' experience presenting its applicability and limits. It is highlighted that the method is not effective in patients with type 2 diabetes. Presenting their results the authors emphasize that this method provides extra information compared to the classical measurements leading to a better glycemic control and life expectancy in type 1 diabetes patients.


Subject(s)
Blood Glucose Self-Monitoring , Blood Glucose/metabolism , Diabetes Mellitus/blood , Diabetes Mellitus/therapy , Adolescent , Adult , Blood Glucose Self-Monitoring/instrumentation , Blood Glucose Self-Monitoring/methods , Child , Diabetes Mellitus/drug therapy , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/therapy , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/therapy , Female , Glycated Hemoglobin/metabolism , Humans , Male
6.
Diabetes Metab Res Rev ; 23(4): 276-85, 2007 May.
Article in English | MEDLINE | ID: mdl-17103487

ABSTRACT

BACKGROUND: Aim of this trial was to test whether heat shock protein peptide DiaPep277 treatment in adult and paediatric patients with recent-onset type 1 diabetes (T1D) is safe and whether it can preserve endogenous insulin production. METHODS: Two studies were performed in a prospective, multicentre, double-blind, placebo-controlled trial. Fifty adult (study p520, aged 16-44 years) and 49 paediatric patients (study p521, 4-15 years) with recent-onset T1D were treated subcutaneously at four different time points with 0.2 mg or 1.0 mg DiaPep277 versus placebo and followed for 18 months. Adult patients were treated with 0.2 mg, 1.0 mg or 2.5 mg DiaPep277 versus placebo. Stimulated C-peptide served as readout for functional beta-cell-mass. RESULTS: DiaPep277-treatment was not associated with severe side effects. No differences were found in placebo and DiaPep277 treated groups. In adults, a modest trend towards better maintenance of beta-cell function was observed in the 0.2 mg and 1.0 mg group, while there was significant loss of stimulated C-peptide in the placebo and 2.5 mg group. Paediatric patients with low HLA risk showed stable C-peptide levels until 13 months upon treatment with 1 mg DiaPep277. Despite similar stimulated C-peptide levels at baseline, children exhibited a more pronounced loss of beta-cell function over 18 months than adults (p = 0.0003). CONCLUSION: Administration of DiaPep277 seems safe and may have beneficial effects on C-peptide levels over time in some patients with T1D, but this finding was not accompanied by reduced HbA1c or insulin requirement. Studies with more patients and longer follow-up are needed to further study the effect of DiaPep277.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Peptides/therapeutic use , Adolescent , Adult , Autoantibodies/blood , C-Peptide/blood , Chaperonin 60 , Child , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/pathology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Therapy, Combination , Glycated Hemoglobin/metabolism , HLA Antigens/blood , HLA Antigens/classification , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/therapeutic use , Injections, Subcutaneous , Insulin/administration & dosage , Insulin/therapeutic use , Insulin-Secreting Cells/pathology , Islets of Langerhans/immunology , Peptide Fragments , Peptides/administration & dosage , Peptides/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...